We will do this by using …
Targeting four viruses, we have defined the following project objectives.
The project is divided into 4 work packages (WPs), each with its own set of milestones and deliverables. A brief description of each WP is provided over the sections below.
WP1 aims at assessing ageing effects on infection- and vaccine-induced immune responses. WP1 will evaluate human immune responses to infection with influenza virus, TBEV, MERS-CoV and/or SARS-CoV-2, and human immune responses to influenza, YF, TBE, MERS and/or SARS-CoV-2 vaccination. Specifically, the expression levels of immunosenescence markers, the strength and functionality of vaccine-specific T cell responses and the efficacy of antibody-mediated immunity will be compared in older vs. younger individuals, in relation to vaccine safety, efficacy and (break-through) infection. Data will be stratified for age and gender.
WP2 aims at the selection of kinase inhibitors and inflammageing modulators that effectively overcome T cell senescence while limiting unproductive inflammation ex vivo. Data will be stratified according to age and gender.
WP3 aims at assessing the capacity of lead combinations of immunomodulators, to improve the efficacy of licensed vaccines and vaccine candidates in animal models.
WP4 aims at evaluation of the (improved) safety, tolerability and immunogenicity in human volunteers of the most promising seasonal influenza vaccine improved with the lead combination of immunomodulators, based on results obtained upon in WP3 in vivo studies.
WP5 will support the overall scientific and financial management of the project, including scientific and financial reporting, assessment of progress towards the project’s objectives, evaluation of deviations and implementation of mitigation measures. It will also be responsible for the development and implementation of dissemination, protection and exploitation of ISOLDA’s results, and will oversee ISOLDA’s communication activities.
WP1 aims at assessing ageing effects on infection- and vaccine-induced immune responses. WP1 will evaluate human immune responses to infection with influenza virus, TBEV and SARS-CoV-2, and human immune responses to influenza, YF, TBE and SARS-CoV-2 vaccination. Specifically, the expression levels of immunosenescence markers, the strength and functionality of vaccine-specific T cell responses and the efficacy of antibody-mediated immunity will be compared in older vs. younger individuals, in relation to vaccine safety, efficacy and (break-through) infection. Data will be stratified for age and gender.
WP2 aims at the selection of kinase inhibitors and inflammageing modulators that effectively overcome T cell senescence while limiting unproductive inflammation ex vivo. Data will be stratified according to age and gender.
WP3 aims at assessing the capacity of lead combinations of immunomodulators, to improve the efficacy of licensed vaccines and vaccine candidates in animal models.
WP4 aims at evaluation of the (improved) safety, tolerability and immunogenicity in human volunteers of the most promising seasonal influenza vaccine improved with the lead combination of immunomodulators, based on results obtained upon in WP3 in vivo studies.
WP5 will support the overall scientific and financial management of the project, including scientific and financial reporting, assessment of progress towards the project’s objectives, evaluation of deviations and implementation of mitigation measures. It will also be responsible for the development and implementation of dissemination, protection and exploitation of ISOLDA’s results, and will oversee ISOLDA’s communication activities.
